Suggested remit: To appraise the clinical and cost effectiveness of remimazolam within its marketing authorisation for sedation for people having diagnostic or therapeutic procedures.
Status Proposed
Process STA 2018
ID number 3758

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 October 2020 (10:00) Scoping workshop
18 August 2020 - 16 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance